What is X‑linked Dominant Retinitis Pigmentosa?
Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies that cause progressive loss of photoreceptor cells, leading to night‑vision problems, peripheral visual field loss, and eventually central vision loss. X‑linked dominant retinitis pigmentosa (XLRP‑D) is a rare genetic form that follows an X‑linked dominant inheritance pattern. Because the responsible gene(s) are located on the X chromosome, males and females can be affected, but the disease often presents earlier and more severely in males.
Patients typically notice symptoms in childhood or early adolescence, although the age of onset can vary. The condition is progressive, meaning symptoms worsen over time. While there is no cure, advances in genetic testing, retinal imaging, and emerging gene‑therapy trials are improving diagnosis and management.
Common Causes
Unlike “causes” in an infectious disease, X‑linked dominant RP is caused by pathogenic variants in specific genes. The most frequently implicated genes include:
- RP2 – Mutations in RP2 are the leading cause of X‑linked RP and are responsible for 10‑15 % of all RP cases.
- OFDM1 (Ocular vs. systemic disease‑related gene 1) – Rare, but documented in a few families.
- RHO (Rhodopsin) – Dominant X‑linked variants – Very uncommon; most RHO mutations are autosomal dominant, but a few X‑linked forms have been described.
- CRX – Transcription factor mutations that can be X‑linked dominant.
- PRPF31 – Typically autosomal dominant; however, X‑linked dominant presentations have been reported.
- CLRN1 (Usher syndrome type 3) – May present with RP‑like changes when X‑linked.
- NYX – Associated with congenital stationary night blindness but can overlap with RP phenotypes.
- BCOR – Mutations cause ocular anomalies including RP in rare X‑linked cases.
- ATPase subunit genes (e.g., ATP1A3) – Rarely cause vision loss that mimics RP.
- Unidentified X‑linked loci – Up to 20 % of X‑linked RP families still have no identified genetic mutation.
Associated Symptoms
Because RP primarily affects the retina, additional ocular and systemic findings may accompany X‑linked dominant RP:
- Night blindness (nyctalopia) – The earliest complaint, often noticed when children first drive at night.
- Peripheral visual field loss – Described as “tunnel vision” as the disease progresses.
- Decreased visual acuity – Central vision may stay relatively preserved until late stages.
- Photopsia (flashes of light) – Caused by retinal degeneration.
- Cataracts – Posterior subcapsular cataracts are common in RP patients.
- Macular edema – Swelling at the central retina, which can accelerate visual loss.
- Reduced contrast sensitivity – Difficulty distinguishing subtle shades.
- Abnormal electroretinogram (ERG) findings – Blunted or absent rod responses.
- Possible systemic features – In rare X‑linked forms, mild intellectual disability, skeletal anomalies, or hearing loss can coexist.
When to See a Doctor
Prompt evaluation is important because early interventions (e.g., low‑vision aids, cataract surgery, or clinical trial enrollment) can preserve quality of life.
- Difficulty seeing in dim lighting or at night, especially if it’s new or worsening.
- Noticing “blurry edges” or a shrinking field of view.
- Frequent tripping, bumping into objects, or difficulty navigating unfamiliar spaces.
- Family history of RP, early‑onset cataracts, or unexplained vision loss.
- Sudden change in vision, new flashes, or floaters (see Emergency Warning Signs below).
Diagnosis
Diagnosing X‑linked dominant RP involves a combination of clinical examination, imaging, functional testing, and genetic analysis.
1. Detailed ophthalmic history & family pedigree
Identifying an X‑linked inheritance pattern helps guide genetic testing. A pedigree chart spanning at least three generations is recommended.
2. Visual acuity and refraction testing
Establishes baseline central vision and corrects refractive errors that may exacerbate symptoms.
3. Fundus examination
Typical RP findings include:
- Bone‑spicule pigment clumping in the mid‑peripheral retina.
- Attenuated retinal blood vessels.
- Optic disc pallor.
4. Wide‑field retinal imaging (Fundus photography & Autofluorescence)
Helps document the extent of retinal degeneration and monitor progression.
5. Optical Coherence Tomography (OCT)
Detects macular edema, thinning of the photoreceptor layer, and peripheral retinal changes.
6. Electroretinography (ERG)
Measures rod and cone function. In RP, rod responses are usually absent or severely reduced, while cone responses decline later.
7. Genetic testing
Next‑generation sequencing panels that include RP2, OFDM1, RHO, CRX, and other X‑linked genes provide a definitive diagnosis. Testing is usually performed on a blood sample; some labs accept saliva.
Guidelines: The American College of Medical Genetics (ACMG) and the National Eye Institute (NEI) recommend genetic confirmation when RP is suspected, especially for patients considered for gene‑therapy trials.
Treatment Options
While no treatment reverses retinal cell loss, several strategies can slow progression, manage complications, and improve visual function.
Medical & Surgical Interventions
- Vitamin A supplementation – Historically used (15,000 IU/day) but now controversial; recent studies suggest modest benefit only in selected patients without liver disease. Must be supervised by a physician (Mayo Clinic).
- Omega‑3 fatty acids (DHA/EPA) – Some evidence of retinal protective effects; can be taken as fish‑oil supplements.
- Cataract surgery – Posterior subcapsular cataracts often develop; phacoemulsification with intra‑ocular lens implantation restores vision.
- Carbonic anhydrase inhibitors (CAIs) – Topical dorzolamide or oral acetazolamide can reduce cystoid macular edema in up to 30 % of patients.
- Anti‑VEGF injections – Occasionally used if secondary neovascular complications arise.
- Gene‑therapy trials – Ongoing Phase I/II trials targeting RP2 mutations (e.g., AAV‑RP2 vectors). Enrollment criteria are strict; consult a retinal specialist or ClinicalTrials.gov for updates.
- Retinal prostheses – The Argus II epiretinal implant is FDA‑approved for severe RP; may be considered when vision is <20/400.
Low‑Vision Rehabilitation
- High‑contrast reading glasses or electronic magnifiers.
- Dark‑adapted (yellow‑tinted) lenses for night driving.
- Orientation and mobility training (orientation and mobility specialists).
- Smartphone apps with voice‑over and screen‑reading capabilities.
Lifestyle & Supportive Measures
- Regular eye‑exam schedule (every 6–12 months) to monitor progression.
- Protect eyes from excessive UV light by wearing sunglasses with 400 nm cutoff.
- Maintain a balanced diet rich in leafy greens, carrots, and lutein/zeaxanthin sources.
- Avoid smoking – tobacco worsens oxidative stress on the retina.
- Engage in patient support groups (e.g., Foundation Fighting Blindness).
Prevention Tips
Because X‑linked dominant RP is genetic, primary prevention (preventing the disease from occurring) is not possible. However, secondary prevention—reducing the impact of the disease—includes:
- Genetic counseling for affected families; carriers can receive reproductive guidance (pre‑implantation genetic diagnosis or prenatal testing).
- Early detection – Family members should undergo baseline retinal screening even if asymptomatic.
- Prompt treatment of modifiable complications (cataracts, macular edema) before they cause irreversible damage.
- Environmental protection – Use UV‑blocking sunglasses and avoid prolonged exposure to bright screens without breaks (20‑20‑20 rule).
- Control systemic health – Manage diabetes, hypertension, and hyperlipidemia, which can exacerbate retinal degeneration.
Emergency Warning Signs
If any of the following occur, seek immediate medical attention (emergency department or ophthalmology on call):
- Sudden, painless loss of vision in one eye.
- Rapid increase in floaters accompanied by flashes of light.
- New onset severe eye pain, redness, or swelling.
- Signs of retinal detachment (curtain‑like shadow across vision).
- Acute onset of double vision or severe headache suggesting intracranial involvement.
**References**
- Mayo Clinic. “Retinitis Pigmentosa.” https://www.mayoclinic.org
- National Eye Institute (NEI). “Genetics of Retinitis Pigmentosa.” https://nei.nih.gov
- American Academy of Ophthalmology. “Retinitis Pigmentosa Clinical Practice Guidelines.” 2023.
- World Health Organization. “Vision Impairment and Blindness.” 2022.
- ClinicalTrials.gov. “AAV‑RP2 Gene Therapy for X‑linked RP.” Accessed 2026.